Development of a Core Set of Outcome Measures for Large-vessel Vasculitis: Report from OMERACT 2016

Sreih A. G., Alibaz-Oner F., Kermani T. A., Aydin S. Z., Cronholm P. F., Davis T., ...Daha Fazla

JOURNAL OF RHEUMATOLOGY, cilt.44, sa.12, ss.1933-1937, 2017 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 44 Sayı: 12
  • Basım Tarihi: 2017
  • Doi Numarası: 10.3899/jrheum.161467
  • Dergi Adı: JOURNAL OF RHEUMATOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1933-1937
  • Anahtar Kelimeler: GIANT CELL ARTERITIS, TAKAYASU ARTERITIS, VASCULITIS, OUTCOME ASSESSMENT, GIANT-CELL ARTERITIS, QUALITY-OF-LIFE, ERYTHROCYTE SEDIMENTATION-RATE, C-REACTIVE PROTEIN, DOUBLE-BLIND TRIAL, TAKAYASU-ARTERITIS, ACTIVITY SCORE, DISEASE-ACTIVITY, POLYMYALGIA-RHEUMATICA, ABATACEPT CTLA-4IG
  • İstanbul Üniversitesi Adresli: Evet

Özet

Objective. Among the challenges in conducting clinical trials in large-vessel vasculitis (LVV), including both giant cell arteritis (GCA) and Takayasu arteritis (TA), is the lack of standardized and meaningful outcome measures. The Outcome Measures in Rheumatology (OMERACT) Vasculitis Working Group initiated an international effort to develop and validate data-driven outcome tools for clinical investigation in LVV.